This investment firm is headquartered in Asia with offices in North America and focuses on early-stage investments in life sciences and healthcare. The firm typically participates in pre-Series A to Series B financing rounds, with initial investment sizes ranging from several hundred thousand dollars to several million dollars and the potential for follow-on investments. The firm seeks opportunities primarily in Europe, as well as North America and the United Kingdom. The firm is open to both leading and co-investing in financing rounds. 

The firm is interested in therapeutics, medical devices, and diagnostics. The firm is open to evaluating digital health and AI-related companies but has limited investment activity in these areas to date. The firm takes an opportunistic approach across subsectors and indications, with areas of interest including immunology, immuno-oncology, central nervous system disorders, and kidney-related diseases. 

For therapeutics, the firm considers opportunities from Phase I and beyond, particularly companies with proof-of-concept data or clinical validation supporting their technologies. For medical devices and diagnostics, the firm generally seeks more mature companies with products or prototypes in development, along with clear regulatory approval strategies. 

The firm does not have specific requirements for management teams but prefers to work with founding teams that have prior entrepreneurial experience.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

This single-family office represents private family interests in the United States. The firm is flexible in terms of investment size but generally looks to invest at least several hundred thousand dollars per round, depending on round size and anticipated capital requirements. The firm prefers Series A and later-stage companies, while pre-Series A opportunities are considered depending on technology maturity. Currently, the firm invests primarily in companies based in North America. 

The firm seeks breakthrough technologies with a strong social impact focus in the therapeutics, medical devices, and diagnostics sectors that address underserved medical needs or provide innovative and disruptive approaches to existing medical procedures and treatments. Areas of particular interest include optical and sound-based technologies, devices that reduce reliance on drug-based treatments, orthopedics, gene and nucleic acid-based therapies, immuno-oncology, and technologies addressing sensory loss. 

The firm reviews co-investment opportunities in private companies and, on an opportunistic basis, may consider investments in micro- and small-cap public companies as a direct investor. The firm seeks companies that have completed seed financing and have reached key intellectual property milestones, including allowance of claims by relevant patent authorities. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

This venture capital firm was founded in the mid-2000s and manages approximately $100 million in assets across multiple funds. The firm makes equity investments ranging from several hundred thousand dollars to several million dollars, with additional capital reserved for follow-on rounds. The firm invests in companies located throughout North America and Europe and plans to make several new investments over the next year. The firm invests in both early-stage companies and later-stage commercial growth opportunities. 

The firm focuses on companies developing medical devices, diagnostics, and healthcare IT products, with an emphasis on capital-efficient technologies that can reach the market quickly and reduce the cost of delivering quality healthcare. The firm is open to a broad range of subsectors and indications within medical technology, with particular interest in technologies related to cardiovascular health and neurological applications. 

The firm seeks companies with skilled and experienced management teams. The firm generally looks to take board seats in portfolio companies after investment and plays an active role in supporting company growth and strategic decisions.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

The firm is an early-stage venture capital firm that primarily invests at the Seed and Series A stages, often serving as the first institutional investor in its portfolio companies. Initial investments typically range from approximately $500K to $7M, with the capacity to invest $15M or more over the life of a company. The firm invests globally but maintains a strong focus on opportunities emerging from major innovation hubs in the United States. The firm follows a thesis-driven investment strategy centered on building category-defining companies addressing large, underserved markets.  

Within healthcare, the firm invests in medical technology, medical devices, diagnostics, genomics-enabled diagnostics, bioinformatics platforms, laboratory services, and other data-driven healthcare businesses. The firm seeks disruptive technologies capable of transforming large clinical markets, with particular interest in opportunities addressing diabetes, cardiovascular disease, hypertension, obesity, and other significant unmet healthcare needs. The firm emphasizes scalable business models, differentiated innovation, and the potential to create or redefine large markets.  

From a company and management team perspective, the firm frequently serves as the lead or co-lead investor and takes an active board role. The firm works closely with portfolio companies on strategy, executive recruitment, product development, commercialization, and fundraising. While experienced leadership teams are valued, the firm is also willing to back first-time founders who demonstrate exceptional vision, technical expertise, and the ability to execute against large market opportunities. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

The firm is an international venture capital firm focused on investing in clinical-stage healthcare companies. The firm invests primarily in companies advancing therapeutic programs while also considering opportunities in diagnostics, medical devices, and digital health. The firm generally targets companies conducting Phase I or Phase II clinical trials or equivalent stages of development and invests across major healthcare markets.  

The firm’s primary focus is therapeutics, although it remains open to diagnostics, medical devices, and digital health opportunities. The firm is generally indication-agnostic but has particular interest in diabetes, pulmonology, ophthalmology, oncology, and other areas with significant unmet medical need. The firm prioritizes companies with meaningful clinical validation and strong translational potential.  

From a company and management team perspective, the firm typically participates as a co-investor and generally prefers opportunities that already have a lead investor in place. The firm does not typically require board representation and does not have specific management team requirements, allowing it to work with a broad range of experienced and emerging leadership teams. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.